Rifampin and pyrazinamide for treatment of latent tuberculosis infection [7]

Clinical Infectious Diseases

Volumn 42, Issue 6, 2006, Pages 892-

  Cook, Paul P ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PYRAZINAMIDE; RIFAMPICIN;

ANTIBIOTIC THERAPY; ENZYME SPECIFICITY; HOSPITALIZATION; HUMAN; LETTER; LIVER INJURY; LIVER TOXICITY; PRIORITY JOURNAL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HOSPITALIZATION; HUMANS; LIVER DISEASES; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS;

EID: 33644834037     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/500458     Document Type: Letter

References (4)

1. McElroy PD, Ijaz K, Lambert LA, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005; 41:1125-33.
2. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis. Chest 2003; 123:102-6.
3. Priest DH, Vossel LF, Sherfy EA, Hoy DP, Haley CA. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. Clin Infect Dis 2004; 39:1764-71.
4. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005; 172:367-79.